Gilead Sciences (GILD) Is Among The Best Extremely Profitable Stocks To Buy According To Wall Street Analysts

With a nett income borderline of 31.00% and upside imaginable of 24.20%, Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the best highly profitable stocks to bargain according to Wall Street analysts. The institution reported nett income of $8.51 cardinal for the precocious completed fiscal twelvemonth (FY25). That momentum continued into 2026, drafting expert attention.

A technician investigating a recently developed immunotherapy cause successful a objective laboratory.

On May 8, 2026, Truist raised its terms people connected Gilead Sciences, Inc. (NASDAQ:GILD) to $157 from $155, portion keeping a “Buy” standing connected the shares. The steadfast pointed to the company’s Q1 top- and bottom-line beat, raised FY26 gross guide, and continued spot successful HIV portfolio, peculiarly Yeztugo.

Gilead Sciences, Inc. (NASDAQ:GILD)’s first-quarter update, released connected May 7, 2026, provided discourse for Truist’s bullish view.

Gilead Sciences, Inc. (NASDAQ:GILD) earned $2.03 per stock connected an adjusted basis, $0.12 supra the mean estimation compiled by LSEG. Revenue moved 4% higher to $6.96 billion, besides clearing Wall Street’s $6.91 cardinal consensus.

The HIV portfolio remained the company’s strongest maturation driver.

Biktarvy income roseate 7% to $3.36 billion, modestly supra the $3.32 cardinal estimate, portion Descovy, an older HIV pill, saw its income leap a stronger-than-expected 38% to $807 million. Yeztugo, the twice-yearly HIV prevention injection launched successful the U.S. past year, posted first-quarter income of $166 million, up of the $143 cardinal forecast.

Management’s raised guidance reflected that strength. Gilead Sciences, Inc. (NASDAQ:GILD) present expects Yeztugo income of $1 cardinal for full-year 2026, up from its anterior $800 cardinal estimate. The institution besides raised its wide 2026 income outlook by $400 million, putting the caller scope astatine $30 cardinal to $30.4 billion.

Meanwhile, the updated net outlook reflected acquisition-related charges alternatively than a alteration successful the underlying forecast. Gilead Sciences, Inc. (NASDAQ:GILD) present projects an adjusted nonaccomplishment of $0.65 to $1.05 per stock for 2026, versus its earlier nett forecast of $8.45 to $8.85. CFO Andrew Dickinson said the accommodation incorporates an $11.5 cardinal second-quarter complaint tied to the Arcellx, Ouro Medicines, and Tubulis acquisitions. Excluding that charge, the net forecast remains unchanged.

Truist said aboriginal Yeztugo persistency signals stay cardinal to the company’s thesis for durable maturation toward a $7 billion-plus highest gross opportunity.

Gilead Sciences, Inc. (NASDAQ:GILD) is simply a cause shaper that develops medicines for unmet aesculapian needs. The institution provides treatments for HIV-1, chronic hepatitis C, superior biliary cholangitis, chronic hepatitis B, and superior invasive fungal infections. It besides offers T-cell and CAR T-cell therapies for big patients, intravenous injections, and treatments for COVID-19.